Evidence map›Paper›PMID 32332845›Full record

ArticleScientific reports2020

The high protein expression of FOXO3, but not that of FOXO1, is associated with markers of good prognosis.

François Lallemand, Sophie Vacher, Leanne de Koning, Ambre Petitalot, Adrien Briaux, Keltouma Driouch, Céline Callens, Anne Schnitzler, Caroline Lecerf, Floriane Oulie-Bard and 7 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. The Role of the Fox Gene in Breast Cancer Progression.International journal of molecular sciences · 2025
    Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 1 country.

François LallemandService de génétique, unité de pharmacogénomique, Institut Curie, 26 rue d'Ulm, Paris, France.
Sophie VacherService de génétique, unité de pharmacogénomique, Institut Curie, 26 rue d'Ulm, Paris, France.ORCID http://orcid.org/0000-0002-0042-6023
Leanne de KoningTranslational Research Department, Institut Curie, PSL Research University, 26 rue d'Ulm, Paris, France.
Ambre PetitalotService de génétique, unité de pharmacogénomique, Institut Curie, 26 rue d'Ulm, Paris, France.
Adrien BriauxService de génétique, unité de pharmacogénomique, Institut Curie, 26 rue d'Ulm, Paris, France.
Keltouma DriouchService de génétique, unité de pharmacogénomique, Institut Curie, 26 rue d'Ulm, Paris, France.
Céline CallensService de génétique, unité de pharmacogénomique, Institut Curie, 26 rue d'Ulm, Paris, France.
Anne SchnitzlerService de génétique, unité de pharmacogénomique, Institut Curie, 26 rue d'Ulm, Paris, France.
Caroline LecerfTranslational Research Department, Institut Curie, PSL Research University, 26 rue d'Ulm, Paris, France.
Floriane Oulie-BardTranslational Research Department, Institut Curie, PSL Research University, 26 rue d'Ulm, Paris, France.
Aurélie BarbetTranslational Research Department, Institut Curie, PSL Research University, 26 rue d'Ulm, Paris, France.
Anne VincentCentre de Recherche en Cancérologie de Lyon (CRCL)/INSERM U1052-CNRS UMR5286 Centre Léon Bérard, 28 Rue Laënnec, 69373 Cedex 08, Lyon, France., Lyon, France.
Sophie Zinn-JustinLaboratoire de Biologie Structurale et Radiobiologie, Institute for Integrative Biology of the Cell (CEA, CNRS, University Paris South), University Paris-Saclay, Gif-sur-Yvette, France.
Bernard S LopezCNRS UMR 8200, Gustave Roussy Cancer Institute, Université Paris-Saclay, équipe labélisée par la Ligue contre le cancer, Villejuif, France.
Rosette LidereauService de génétique, unité de pharmacogénomique, Institut Curie, 26 rue d'Ulm, Paris, France.
Ivan Bieche *Service de génétique, unité de pharmacogénomique, Institut Curie, 26 rue d'Ulm, Paris, France.
Sandrine M Caputo *Paris Sciences Lettres Research University, Paris, France. sandrine.caputo@curie.fr.ORCID http://orcid.org/0000-0001-5338-9388
Institut Curie · FRUniversité Paris Sciences et Lettres · FRCentre National de la Recherche Scientifique · FRDélégation Paris 5 · FRLaboratoire Jean Perrin · FRUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To better define the role of FOXO1 and FOXO3 transcriptional factors in breast carcinogenesis, we performed a comparative study of their expression at both the RNA and protein levels in a series of human breast tumors. We used qRT-PCR assay to quantify mRNA expression and Reverse Phase Protein Arrays (RPPA) to quantify protein expression in 218 breast tumors from patients with known clinical/pathological status and outcome. Weak correlations were observed between mRNA and protein expressions for both FOXO1 and FOXO3 genes. High expression of FOXO3 protein, but not FOXO1 protein, was a good prognostic marker, negatively correlated with KI67 and markers of activity of the PI3K/AKT/mTOR oncogenic pathway, and positively correlated with p53, a marker of apoptosis. Moreover, FOXO3 protein expression, but not FOXO1 protein expression, was also negatively correlated with various proteins involved in different DNA repair mechanisms. FOXO3 protein, but not FOXO1 protein, appears to be a tumor suppressor that inhibits breast cancer by altering DNA damage response (DDR), thereby inducing p53-dependent apoptosis. This antitumor effect appears to be suppressed by excessive activity of the PI3K/AKT/mTOR pathway. High FOXO3 protein expression could be a biomarker of deficient DDR in breast tumors.

Indexed as

AdultAgedAged, 80 and overApoptosisBiomarkers, TumorBreast NeoplasmsCell CycleCell ProliferationDNA DamageDNA RepairFemaleForkhead Box Protein O1Forkhead Box Protein O3Gene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateBiomarkers, TumorForkhead Box Protein O1Forkhead Box Protein O3FOXO1 protein, humanFOXO3 protein, humanMTOR protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, MessengerTOR Serine-Threonine Kinases

Identifiers

PMID32332845
PMCPMC7181619
OpenAlexW3019916529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.